An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy

Jieyang People's Hospital

Status and phase: Not yet enrolling; Early Phase 1

Conditions: IgA Nephropathy (IgAN)

Treatments: Biological: anti-CD19/BCMA CAR NK cells

Study type: Interventional

Funder types: Other

Identifiers

NCT06926985

2025002

Details and patient eligibility

About

A single arm, open-label pilot study is designed to evaluate the safety and effectiveness of anti-CD19/BCMA CAR NK cells (KN5601) in patients with IgA nephropathy

Enrollment: 36 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age: ≥ 18 years old and ≤ 70 years old, male or female;
2. IgA nephropathy confirmed by pathological biopsy of renal biopsy;
3. All females of childbearing potential must use effective contraception during treatment and for 90 days after the last dose of treatment. In addition, subjects must not donate eggs during the study and for at least 90 days after the last dose of treatment;
4. Urine total protein/urine creatinine ratio (UPCR) ≥ 500 mg/g and estimated glomerular filtration rate (eGFR) > 20 ml/min/1.73m2 during the screening period

Exclusion criteria

1. Subjects with IgA nephropathy with rapidly progressive renal function, pathological manifestations include extensive crescent formation and necrotic vascular lesions in the glomeruli;
2. Secondary IgA nephropathy;
3. Subjects do not take medication regularly or stop taking medication during treatment;
4. Individuals with known severe allergic reactions, hypersensitivity, contraindication to any medications during the trial (cyclophosphamide, fludarabine, tozumabs), or subjects with a history of severe allergic reactions;
5. Subjects with active infection (except simple urinary tract infection and bacterial pharyngitis), or currently receiving intravenous antibiotic treatment, or subjects who have received intravenous antibiotic treatment within 1 week before KN5601 infusion;
6. Subjects with acquired and congenital immunodeficiency diseases;
7. Subjects with grade III or IV heart failure (NYHA classification);
8. History of epilepsy or other central nervous system (CNS) diseases;
9. History of severe herpes infection, such as herpes encephalitis, ocular herpes, or disseminated herpes; signs of herpes or varicella-zoster virus infection (especially chickenpox, herpes zoster) within 12 weeks prior to screening;
10. History of other primary malignant tumors except:
11. Cured non-melanoma skin cancer by surgical excision, for example basal cell carcinoma (BCC) ;
12. Cured primary malignant tumors, such as cervical cancer, superficial bladder cancer, breast cancer
13. Has a history of any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urinary, pulmonary, neurological, dermatologic, psychiatric, and renal disease or other significant disease that precludes KN5601 administration (as determined by the investigator), except IgA nephropathy;
14. Females who are pregnant, lactating, or planning a pregnancy within six months;
15. Subjects who have received other clinical trial treatment within 3 months;
16. Subjects who have received B cell-targeted drug therapy within 1 months before enrollment;
17. Any abnormal laboratory test results judged by the investigator to be clinically significant and prevent the subject from participating in the study. Laboratory test values that are out of range and not of clinical significance will not be considered as exclusion criteria;
18. Any situation judged by the investigators that may increase the risk of the subjects or interfere with the clinical trial outcome

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

36 participants in 1 patient group

anti-CD19 BCMA CAR NK cells

Experimental group

Treatment:

Biological: anti-CD19/BCMA CAR NK cells